REG - ValiRx PLC - Collaboration Agreement with Voxcell BioInnovation

ValiRxAnnouncement

29/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8879Sa&default-theme=true

RNS Number : 8879S  ValiRx PLC  29 July 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Collaboration Agreement with Voxcell BioInnovation

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to announce the execution of a collaboration agreement
(the "Agreement") with Canada based VoxCell BioInnovation Inc. ("VoxCell") to
provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and use in
VoxCell's proprietary fully perfusable vascularised 3D tissue culture
models.  The Agreement initially focusses on establishment of three Triple
Negative Breast Cancer ("TNBC") in-vitro 3D tumour models which can then be
offered for commercial sale and/or services by VoxCell and/or Inaphaea.

As part of the Agreement, three TNBC PDC models will be expanded and
tested/optimised for growth on VoxCell's Bioink matrix at Inaphaea's facility.
PDCs will then be transferred to VoxCell to generate vascularised 3D cell
culture models and further evaluated. Both parties plan to jointly publish the
results.

 

Mark Eccleston, CEO of ValiRx commented "We continue to build partnerships
that expand the markets for our PDC models and testing services, particularly
in the ex-vivo space considering the FDA's decision to phase out animal-based
testing requirements for new drug filings. This Agreement with VoxCell
exemplifies our approach to leverage commercial access to our biobank with
services and technologies that complement our internal pipeline development
and is a real opportunity to develop valuable data to progress our Clx001
oncolytic peptide asset whilst exemplifying the utility of our PDC models in
combination with a next generation, non-animal-based testing platform.
VoxCell's perfused 3D culture platform is well positioned for testing aspects
of nano-formulated drug delivery such as targeting, tumour accumulation from
the vasculature and penetration into solid tumours."

 

Karolina Valente, CEO of VoxCell commented "We are proud to partner with
ValiRx to accelerate the development of physiologically relevant TNBC models.
By combining their PDC models with our vascularized 3D bioprinting technology,
we will create more predictive, human-like tumour tissues for drug screening.
Integrating clinically relevant cells from ValiRx into our high-resolution
vascular networks will allow us to support the assessment of ValiRx's Clx001
oncolytic peptide asset in a highly translational environment. This
collaboration not only aims to generate valuable efficacy and tumor
penetration data for Clx001, but also sets the foundation for expanding our
partnership to other cancer indications, leveraging the breadth of ValiRx's
PDC model biorepository and VoxCell's advanced, perfused tissue models.
Together, we are helping shape a future where complex cancers like TNBC are
studied and treated with greater precision and confidence."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/aP3wwP

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRRPMLTMTATBIA